Literature DB >> 23054401

Macrovascular thrombosis in critically ill patients with thrombotic micro-angiopathies.

Laurent Camous1, Agnès Veyradier, Michael Darmon, Lionel Galicier, Eric Mariotte, Emmanuel Canet, Nathalie Parquet, Élie Azoulay.   

Abstract

The purpose of this study is to assess the incidence and describe the clinical and pathological features of macrovascular thrombosis during the course of thrombotic micro-angiopathy (TMA) in a 6 year retrospective study of all adults with TMA, admitted to a teaching-hospital ICU. Of the 55 patients identified, all had anaemia and thrombocytopenia and 45 (82 %) had renal or neurological impairment. All patients received plasmapheresis, steroids, and strict blood pressure control. Macrovascular venous or arterial thromboses were diagnosed in 28 (51 %) patients; among them, 7 had cerebral artery thrombosis and 21 (including 13 with central venous catheters) had deep vein thrombosis. Median time from plasmapheresis initiation to thrombosis was 7 (4-10) days. Clinical findings were suggestive of deep venous thrombosis in 7 of the 21 patients (33 %) and only one of the 7 patients with stroke had corresponding clinical signs. By multivariate analysis, factors independently associated with macrovascular thrombosis were undetectable ADAMTS13 activity (odds ratio 7.33, 95 % confidence interval 1.3-41.3), cardiac involvement with TMA (odds ratio, 3.46; 95 % confidence interval, 1.1-13.9) and TMA flare (odds ratio 9.03; 95 % confidence interval 1.03-79.4). In conclusion, half of the patients with TMA experience macrovascular thrombosis. Patients with TTP-related ADAMTS13 deficiency and those with cardiac manifestations of TMA are at higher risk for arterial or deep venous thrombosis.

Entities:  

Mesh:

Year:  2012        PMID: 23054401     DOI: 10.1007/s11739-012-0851-4

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  19 in total

Review 1.  Thrombotic microangiopathies.

Authors:  Joel L Moake
Journal:  N Engl J Med       Date:  2002-08-22       Impact factor: 91.245

2.  Acute myocardial infarction in thrombotic microangiopathies--clinical characteristics, risk factors and outcome.

Authors:  Daniel Patschan; Oliver Witzke; Ulrich Dührsen; Raimund Erbel; Thomas Philipp; Stefan Herget-Rosenthal
Journal:  Nephrol Dial Transplant       Date:  2006-03-30       Impact factor: 5.992

Review 3.  Mechanisms of thrombus formation.

Authors:  Bruce Furie; Barbara C Furie
Journal:  N Engl J Med       Date:  2008-08-28       Impact factor: 91.245

4.  Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.

Authors:  P N Lara; T L Coe; H Zhou; L Fernando; P V Holland; T Wun
Journal:  Am J Med       Date:  1999-12       Impact factor: 4.965

Review 5.  Von Willebrand factor and thrombosis.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  Ann Hematol       Date:  2006-03-28       Impact factor: 3.673

Review 6.  Deep vein thrombosis and its prevention in critically ill adults.

Authors:  J Attia; J G Ray; D J Cook; J Douketis; J S Ginsberg; W H Geerts
Journal:  Arch Intern Med       Date:  2001-05-28

7.  The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency.

Authors:  D R Terrell; L A Williams; S K Vesely; B Lämmle; J A K Hovinga; J N George
Journal:  J Thromb Haemost       Date:  2005-07       Impact factor: 5.824

8.  Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep venous thromboses?

Authors:  R Flamholz; H R Jeon; J M Baron; B W Baron
Journal:  J Clin Apher       Date:  2000       Impact factor: 2.821

9.  The G1691A mutation of the factor V gene (factor V Leiden) and the G20210A mutation of the prothrombin gene as risk factors in thrombotic microangiopathies.

Authors:  Christoph Sucker; Christine Kurschat; Gerd R Hetzel; Bernd Grabensee; Beate Maruhn-Debowski; Robert Loncar; Ljerka Ostojic; Ruediger E Scharf; Rainer B Zotz
Journal:  Clin Appl Thromb Hemost       Date:  2009 May-Jun       Impact factor: 2.389

Review 10.  Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases.

Authors:  Gregory A Hosler; Ana M Cusumano; Grover M Hutchins
Journal:  Arch Pathol Lab Med       Date:  2003-07       Impact factor: 5.534

View more
  4 in total

Review 1.  Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions.

Authors:  Simona Pagliuca; David Michonneau; Flore Sicre de Fontbrune; Aurélien Sutra Del Galy; Aliénor Xhaard; Marie Robin; Régis Peffault de Latour; Gérard Socie
Journal:  Blood Adv       Date:  2019-08-13

2.  What's new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  J Evan Sadler
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2015

3.  Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura.

Authors:  Elie Azoulay; Philippe R Bauer; Eric Mariotte; Lene Russell; Paul Knoebl; Ignacio Martin-Loeches; Frédéric Pène; Kathryn Puxty; Pedro Povoa; Andreas Barratt-Due; Jose Garnacho-Montero; Julia Wendon; Laveena Munshi; Dominique Benoit; Michael von Bergwelt-Baildon; Marco Maggiorini; Paul Coppo; Spero Cataland; Agnès Veyradier; Andry Van de Louw
Journal:  Intensive Care Med       Date:  2019-10-07       Impact factor: 17.440

Review 4.  Severe Thrombotic Thrombocytopenic Purpura (TTP) with Organ Failure in Critically Ill Patients.

Authors:  Sofiane Fodil; Lara Zafrani
Journal:  J Clin Med       Date:  2022-02-19       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.